Comparative Pharmacology
Head-to-head clinical analysis: DOXYCHEL versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCHEL versus TETRACHEL.
DOXYCHEL vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily. For severe infections, continue 100 mg every 12 hours.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
12-22 hours (mean ~16 hours); prolonged in severe hepatic impairment (up to 30 hours).
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Renal (20-30%), biliary/fecal (40-60%), with significant enterohepatic circulation; nonrenal elimination accounts for about 70%.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic